Veliparib: all 94 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 MutationsActive, not recruitingNCT03581292Phase 2Results posted
- Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT03289910Phase 2Results posted
- Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & LymphomaCompletedNCT03061188Phase 1Results posted
- Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal CancerCompletedNCT02921256Phase 2Results posted
- FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic CancerCompletedNCT02890355Phase 2Results posted
- Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid TumorsCompletedNCT02723864Phase 1Results posted
- Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesCompletedNCT02595905Phase 2Results posted
- Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02470585Phase 3Results posted
- A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02412371Phase 1/2Results posted
- Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal CancerCompletedNCT02305758Phase 2Results posted
- Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung CancerCompletedNCT02289690Phase 1/2Results posted
- Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former SmokersCompletedNCT02264990Phase 3Results posted
- A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast CancerCompletedNCT02163694Phase 3Results posted
- Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast CancerCompletedNCT02158507Not applicableResults posted
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02152982Phase 2/3Results posted
- MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene VariationsCompletedNCT01827384Phase 2Results posted
- Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast CancerCompletedNCT01818063Phase 2Results posted
- Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck CancerCompletedNCT01711541Phase 1/2Results posted
- Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung CancerCompletedNCT01657799Phase 2Results posted
- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT01642251Phase 1/2Results posted
- Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung CancerActive, not recruitingNCT01638546Phase 2Results posted
- Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT01585805Phase 2Results posted
- Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01576172Phase 2Results posted
- Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT01540565Phase 2Results posted
- Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasCompletedNCT01514201Phase 1/2Results posted
- Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast CancerCompletedNCT01506609Phase 2Results posted
- ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic CancerCompletedNCT01489865Phase 1/2Results posted
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryActive, not recruitingNCT01386385Phase 1/2Results posted
- Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
- Phase II ABT-888 With CyclophosphamideCompletedNCT01306032Phase 2Results posted
- Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT01266447Phase 2Results posted
- ABT-888 and Temozolomide for Liver CancerTerminatedNCT01205828Phase 2Results posted
- Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast CancerCompletedNCT01149083Phase 2Results posted
- A Study of ABT-888 in Combination With Temozolomide for Colorectal CancerCompletedNCT01051596Phase 2Results posted
- Veliparib and Temozolomide in Treating Patients With Recurrent GlioblastomaCompletedNCT01026493Phase 1/2Results posted
- Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal CancerActive, not recruitingNCT01012817Phase 1/2Results posted
- ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast CancerCompletedNCT01009788Phase 2Results posted
- A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic MelanomaCompletedNCT00804908Phase 2Results posted
- A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerWithdrawnNCT03400306Phase 1
- Study in Patients With SCLC of Veliparib in Combination With TopotecanStatus unknownNCT03227016Phase 1
- Response to PARP Inhibitor Predicted by the RAD51 AssayWithdrawnNCT03044795Phase 2
- Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer PatientsWithdrawnNCT03032614Phase 2
- Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell CancerCompletedNCT02860819Phase 2
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- Liposomal Irinotecan and Veliparib in Treating Patients With Solid TumorsCompletedNCT02631733Phase 1
- Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian CancerCompletedNCT02483104Phase 1
- A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid TumorsCompletedNCT02210663Phase 1
- Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung CancerCompletedNCT02106546Phase 3
- A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerCompletedNCT02032277Phase 3
- A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid TumorsCompletedNCT02009631Phase 1
- Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic CancerCompletedNCT01908478Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid TumorsCompletedNCT01853306Phase 1
- Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT01749397Phase 1
- Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA StatusCompletedNCT01690598Phase 1/2
- Pre-Operative Radiation and Veliparib for Breast CancerCompletedNCT01618357Phase 1
- A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid TumorsCompletedNCT01617928Phase 1
- A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal CancerCompletedNCT01589419Phase 1
- A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung CancerCompletedNCT01560104Phase 2
- Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory MyelomaCompletedNCT01495351Phase 1
- Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast CancerCompletedNCT01477489Phase 1
- Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA MutationCompletedNCT01472783Phase 1/2
- Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT01459380Phase 1
- ABT-888 Plus Metronomic Cyclophosphamide to Treat CancerCompletedNCT01445522Phase 1
- Veliparib and Dinaciclib in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT01434316Phase 1
- ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney ProblemsWithdrawnNCT01419548Phase 1
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
- Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT01351909Phase 1
- Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
- Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical CancerCompletedNCT01281852Phase 1
- Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT01281150Phase 1
- Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerCompletedNCT01264432Phase 1
- Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerActive, not recruitingNCT01251874Phase 1
- Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsTerminatedNCT01233505Phase 1
- To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid TumorsCompletedNCT01199224Phase 1
- To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid TumorsCompletedNCT01193140Phase 2
- ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT01154426Phase 1
- Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast CancerCompletedNCT01145430Phase 1
- Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedNCT01139970Phase 1
- Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid TumorCompletedNCT01123876Phase 1
- A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian CancerCompletedNCT01113957Phase 2
- Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast CancerCompletedNCT01104259Phase 1
- A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate CancerCompletedNCT01085422Phase 1
- A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid TumorsCompletedNCT01063816Phase 1
- A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS TumorsCompletedNCT00994071Phase 1
- ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
- Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyCompletedNCT00892736Phase 1
- Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin LymphomaActive, not recruitingNCT00740805Phase 1
- A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain MetastasesCompletedNCT00649207Phase 1
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
- Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT00576654Phase 1
- Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and LymphomasCompletedNCT00553189Phase 1
- Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid CancerCompletedNCT00535119Phase 1
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsCompletedNCT00526617Phase 1
- ABT-888 in Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00387608Phase 1